Dr. Diego Clemente López, Ph.D.
Principal Investigator
Neuroinmuno-Repair Group (Lab i2-04; office i2-12)
Hospital Nacional de Parapléjicos
Toledo, Spain
ORCID code: orcid.org/0000-0003-4829-9497
Researcher ID: E-2529-2016

1.- ACADEMIC DEGREES

- Degree in Biological Sciences. (1998). University of Salamanca. Salamanca, Spain.
- "Grado de salamanca" (Minor Thesis) (1999). University of Salamanca. Salamanca, Spain.
- Ph.D. In Biology (Neuroscience Program) (2003). University of Salamanca, Spain.

2.- RESEARCH AND PROFESSIONAL EXPERIENCE

- 1997-1998: Collaborative fellowship. Spanish Ministry of Education and Science. Cell Biology and Pathology Department. University of Salamanca. Salamanca, Spain.

- 1999-2002: Ph.D. Student. Spanish Ministry of Education and Science. Cell Biology and Pathology Department. University of Salamanca. Salamanca, Spain.

- 2003- Collaborative professor. School of Biology Facultad de Biología. University of Salamanca. Salamanca, Spain.

- 2004-2006: Postdoctoral research fellow. Spanish Ministry of Education, Culture and Sports. Cajal Institute-CSIC. Madrid, Spain.

- 2006-2010. Postdoctoral researcher. National Hospital for Paraplegics-SESCAM. Toledo, Spain.

- 2011-2015. Senior Postdoctoral researcher. National Hospital for Paraplegics-SESCAM. Toledo, Spain.

- 2015- Present. Principal Investigator. Neuroimmuno-Repair Group. National Hospital for Paraplegics-SESCAM. Toledo, Spain.

- 2023- Present. Principal Investigator. Neuroimmuno-Repair Group Center for Cooperative Research in Neurodegenerative Diseases Network (CIBERNED). Madrid, (Spain)

3.- PUBLICATIONS

3.1. Original papers

2024

del Pilar, C., Garrido-Matilla, L., del Pozo-Filíu, L., Lebrón-Galán, R., **Clemente, D.**, Alonso, J.R., Weruaga, E., Díaz, D. Intracerebellar injection of monocytic immature myeloid cells prevents the adverse effects caused by stereotactic surgery in a model of cerebellar neurodegeneration. J Neuroinflammation. 2024, 21:49. doi: doi.org/10.1186/s12974-023-03000-8

2023

- Ortega, M.C.*, Lebrón-Galán, R.*, Machín-Díaz, I., Naughton, M., Pérez-Molina, I., García-Arocha, J., García-Domínguez, J.M., Goicoechea-Briceño, H., Vila-del Sol, V., Quintanero-Casero, V., García-Montero, R., Galán, V., Calahorra, L., Camacho-Toledano, C., Martínez-Ginés, M.L., Fitzgerald, D., **Clemente, D.** Central and peripheral myeloid-derived suppressor cell-like cells are closely related to the clinical severity of multiple sclerosis. Acta Neuropathol. 2023, 46(2):263-282. doi: 10.1007/s00401-023-02593-x. *Similar contribution.

- Roncancio-Clavijo, A., Gorostidi-Aicua, M., Alberro, A., Iribarren-López, A., Butler, R., López, R., Iribarren, J.A., Clemente, D., Marimón, J.M., Basterrechea, J., Martínez, B., Prada, A., Otaegui, D. Early biochemical analysis of COVID-19 patients helps severity prediction. PLoS One. 2023, 18(5):e0283469. doi: 10.1371/journal.pone.0283469.

2022

- Camacho-Toledano, C., Machín-Díaz, I., Calahorra, L., Cabañas, M., Otaegui, D., Castillo-Triviño, T., Villar, M.L., Costa-Frossard, L., Comabella, M., Midaglia, L., García-Domínguez, J.M., García-Arocha, J., Ortega, M.C., **Clemente, D.** Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis. J. Neuroinflammation, 2022, 19(1):277. doi: 10.1186/s12974-022-02635-3.

2021

- Del Pilar, C., Lebrón-Galán, R., Pérez-Martín, E., Pérez-Revuelta, L., Ávila-Zarza, C.A., Alonso, J.R., **Clemente, D.**, Weruaga, E.*, Díaz, D.* The selective loss of Purkinje cells induces specific peripheral immune alterations. Front CellNeurosci. 2021, 15:773696. *Similar contribution.

- Rosa, J.M*., Farré-Alins, V*., Ortega, M.C., Navarrete, M., López-Rodríguez, A.B., Palomino-Antolín, A., Fernández-López, E., Vila-del Sol, V., Decouty, C., Narros-Fernández, P., **Clemente, D.,** Egea, J. TLR4 path way impairs synap ticnumber and cerebrovascular functions through astrocyte activation following traumatic brain injury. Br J Pharmacol. 2021. 78:3395–3413. doi: 10.1111/bph.15488. (OPEN ACCESS). *Similar contribution.

- Helie, P.*, Camacho-Toledano, C.*,Lesec, L., Seillier, C., Miralles, A.J., Ortega, M.C., Guérit, S., Lebas, H., bardou, I., Vila-del Sol., V., Vivien, D., Le Mauff, B., **Clemente, D.**[#], Docagne, F.[#], Toutirais, O.[#] Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses. J Neuroinflamm. 2021. 18:52. *[#]Similar contribution.

- Melero-Jerez, C., Fernández-Gómez, B., Lebrón-Galán, R., Ortega, M.C., Sánchez de Lara, I., Ojalvo, A.C., **Clemente, D.***, de Castro, F.* Myeloid-derived suppressor cells support remyelination in a murine model of multiple sclerosis by promoting oligodendrocyte precursor cell survival, proliferation, and differentiation. Glia. 2021. 69(4):905-924. *** Similar contribution of both corresponding authors.**

2020

- Melero-Jerez, C., Alonso-Gómez, A., Moñivas, E., Lebrón-Galán, R., Machín-Díaz, I., de Castro, F., **Clemente D***. The proportion of Myeloid-Derived Suppressor Cells in the spleen is related to the severity of the clinical course and tissue damage extent in a murine model of Multiple Sclerosis Neurobiology of Disease. 2020 140:104869. *Corresponding author.

- Malhotra, S., Costa, C., Eixarch, H., Keller, C.W., Amman, L.S., Martínez-Banaclocha, H., Migdalia, L., Sarró, E., Machín-Díaz, I., Villar, L.M., Triviño, J.C., Oliver-Martos, B., Navarro-Parladé, L., Calvo-Barreiro, L., Matesanz, F., Vandenbroeck, K., Urcelay, E., Martínez-Ginés,M.L., Tejeda-Velarde, A., Fissolo, N., Castilló, J., Sánchez, A., Robertson, A.A.B., **Clemente, D.**, Prinz, M., Pelegrin, P., Lünemann, J.D., Espejo, C., Montalbán, X., Comabella, M. NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis. Brain. 2020. 24:1414-1430.

- Calvo-Barreiro, L., Eixarch, H., Ponce-Alonso, M., Castillo, M., Lebrón-Galán, R., Mestre, L., Guaza, C., **Clemente, D.**, del Campo, R., Montalbán, X., Espejo, C. A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis. Cells. 2020. 8:906.

2019

- Melero-Jerez, C., Suardíaz, M., Lebrón-Galán, R., Marín-Bañasco, C., Oliver-Martos, B., Machín-Díaz, I., Fernández, Ó., de Castro, F., **Clemente D***. The presence and suppressive activity of myeloid-derived suppressor cells are potentiated after interferon-β treatment in a murine model of multiple sclerosis. Neurobiology of Disease. 2019 127:13-31. (https://doi.org/10.1016/j.nbd.2019.02.014). ***Corresponding author.**

2018

- Mecha M, Feliú A, Machín-Díaz I, Cordero C, Carrillo-Salinas FJ, Mestre L, Hernández-Torres G, Ortega-Gutiérrez S, López-Rodríguez ML, de de Castro F, **Clemente D[1]** and Guaza C[1] *Corresponding author. 2-AG limits Theiler´s virus induced acute neuroinflammation by modulating microglia and promoting MDSCs. 2018. *Glia*. 66:1447-1463. **[1]Corresponding author.**

2017

- Marín-Bañasco, C., Benabdellah, K., Melero-Jerez, C., Oliver, B., Pinto-Medel, M.J. Hurtado-Guerrero, I. de Castro, F.; **Clemente, D.**, Fernández, Ó., Martín, F., Leyva, L., Suardíaz-García, M Gene Therapy With Mesenchymal Stem Cells Expressing IFNß Ameliorates Neuroinflammation in Experimental Models of Multiple Sclerosis. 2017. *British J Pharmacol*. 174-3: 238-253.

- Leonetti , C., Macrez, R., Pruvost, M., Hommet, Y., Bronsard, J., Fournier, A., Perrigault, M., Machín, I., Vivien, D., **Clemente. D.**, De Castro, F., Maubert, E., Docagne, F. Tissue-type plasminogen activator exerts EGF-like chemokinetic effects on oligodendrocytes in white matter (re)myelination. 2017. *Mol Neurodeg*. 12: 20.

2016

- Macrez, R*., Ortega, M.C*., Bardou, I., Mehra, A., Fournier, A., Van der Pol, S.M.A., Haelewyn, B., Maubert, M., Lesept, F., Chevilley, A., de Castro, F., De Vries, H.E., Vivien, D., **Clemente, D.**[#] and Docagne, F.[#] Neuroendothelial NMDA receptors as therapeutic targets in experimental autoimmune encephalomyelitis. *Brain*. 139: 2406-2419. ***[#]This authors equally contributed to this work.**

- Khan, M., Schultz, S., Fleming, T., Lebrón-Galán, R., **Clemente, D.**, Nawroth, P., Schwaninger, M. Hyperglycemia in stroke impairs polarization of monocytes/macrophages to a protective anti-inflammatory cell type. *J Neurosci*. 36: 9313-9325.

- Suardíaz, M., **Clemente, D.**, Marin-Bañasco, C., Orpez, T., Guerrero-Hurtado, I., Pavía, P., Pinto-Medel, M.J., de Castro, F., Leyva, L., Fernández, Ó., Oliver, B. Recombinant soluble IFN receptor (sIFNAR2)

exhibits intrinsic therapeutic efficacy in a murine model of Multiple Sclerosis *Neuropharmacology*. 110: 480-492.

2014

- Moliné-Velázquez, V. Ortega, M.C., Vila-del Sol, V., Melero-Jerez, C., de Castro, F. and **Clemente, D.[1]** Synthetic Retinoid Am80 abolishes symptom recovery in a model of multiple sclerosis by modulating myeloid-derived suppressor cell fate and viability. *Neurobiol. Dis.* 2014. 67: 149-164.. **[1]Corresponding author.**

2013

- **Clemente, D[1].**, Ortega, M.C., Melero-Jerez, C., de Castro, F. The effect of glia-glia interactions on oligodendrocyte precursor cell biology during development and in demyelinating diseases. *Front. Cell. Neurosci.* Invitation to the Research Topic: "*Glial cells and neuro-glia interactions in the nervous system*". Guest Ed. Martin Stangel. 2013.. **[1]Corresponding author.**

2012

- Ortega-Muñoz, M.C., Cases, O., Merchán, P., Koziraky, R., **Clemente, D.***, de Castro, F*. Megalin mediates the influence of Sonic Hedgehog on oligodendrocyte precursor cell migration and proliferation during development. *Glia.* 2012. 60:851–866. ***This authors equally contributed to this work*.**

2011

- **Clemente, D.,** Ortega, M.C., Arenzana, F.J., de Castro, F. FGF-2 and Anosmin-1 are selectively expressed in different types of multiple sclerosis lesions. *J. Neurosci.* 2011. 31, 14899-14909.

- Moliné-Velázquez, V., Cuervo, H., Vila del Sol, V., Ortega, M.C., **Clemente, D.[1]*,** de Castro, F*. Myeloid-derived suppressor cells limit the inflammation by promoting T lymphocyte apoptosis in the spinal cord of a murine model of multiple sclerosis. *Brain Pathol.* 2011. 21, 678-691. **[1]Corresponding author.*

2010

- García-González, D., **Clemente, D.,** Coelho, M., Esteban, P.F., Soussi-Yanicostas, N., de Castro, F. Dynamic roles of FGF-2 and Anosmin-1 in the migration of neuronal precursors from the subventricular zone during pre- and postnatal development. *Exp. Neurol.* 2010. 222: 285-295.

3.2 Reviews

2022

- Calahorra, L., Camacho-Toledano, C., Serrano-Regal, M.P., Ortega, M.C., **Clemente D.** Regulatory Cells in Multiple Sclerosis: From Blood to Brain. Biomedicines. 2022, 10(2):335. doi: 10.3390/biomedicines 10020335.

- Seillier, C., Hélie, P., Petit, G., Vivien, D., **Clemente, D.,** Le Mauff, B., Docagne, F., Toutirais, O.Roles of the tissue-type plasminogen activator in immune response. Cell Immunol. 2022, 371:104451. doi: 10.1016/j. cellimm.2021.104451.

2016

-_Velázquez, V., Vila-del Sol, V., de Castro, F., y **Clemente, D.** [1] Myeloid cell distribution and functionality in multiple sclerosis. 2016. *Histol Histopathol*. 31: 357-370.**[1]Corresponding author.**

- Melero-Jerez, C., Ortega, M.C. Moliné-Velázquez, V. y **Clemente, D[1]**. Myeloid-derived suppressor cells in neuroimmunolgical diseases BBA-Molecular Basis of Disease. 2016. 1862: 368-380. **[1]Corresponding author.**

2013

- García-González, D., Murcia-Belmonte, V., **Clemente D.**, de Castro, F. Olfactory system and myelination. *Anat Rec.* 2013. 296: 1424-1434.

2012

- Moreno, B., Espejo, C., Mestre, L., Suardíaz, M., **Clemente, D.**, de Castro, F., Fernández, Ó., Montalbán, X., Villoslada, P., Guaza, C. Guide for the adequate use of animal models for the development of new therapies in multiple sclerosis. *Rev. Neurol.* 2012. 54: 114-124.

4.- GRANTED RESEARCH PROJECTS

- The role of IMMUnity in tackling PARKinson's disease through a Translational NETwork (IMMUPARKNET). Cost Action CA21117. European Union. 600,000 € for the whole project. 2023-2027. Principal Investigator. (Coordinator: Dr. Cristoforo Comi).

- Spanish Network for Multiple Sclerosis. Research Networks. (RED2022-134425-T). Ministerio de Ciencia, Innovación y Universidades. 2023-2025. 19,000 €. Principal Investigator (Coordinator of the network: Dr. Fuencisla Matesanz)

- Member of the Center for Cooperative Research in Neurodegenerative Diseases Network (CIBERNED). Instituto de Salud Carlos III (CB22/05/00016). Ministerio de Ciencia, Innovación y Universidades. P.I.: Diego Clemente López. 2023- Present. 96,000 €. Principal Investigator. (Research Director: Dr. Adolfo López de Muniain).

- **A new preclinical strategy with extracellular vesicles to treat severe Multiple Sclerosis: new insight into myelin repair.** Consejería de Educación, Cultura y Deportes (SBPLY/21/180501/000228). Junta de Comunidades de Castilla-La Mancha. P.I. Dr. Diego Clemente López and Dr. Mª Cristina Ortega Muñoz. 2022-2025. 113.147,65 €. Principal Investigator.

- **Immunoregulation in the severity of multiple sclerosis: predictive value and therapeutic perspectives.** Instituto de Salud Carlos III (PI21/00302). Ministerio de Ciencia e Innovación. P.I. Dr. Diego Clemente López. 01/01/2022-31/12/2024. 196.020 €. Principal Investigator.

- **Análisis del componente inmuno-regulador de la respuesta inmune periférica y central como biomarcador de severidad del curso clínico en esclerosis múltiple.** Fundación Merck Salud, en la categoría de Investigación Clínica en Esclerosis Múltiple. P.I. Dr. Diego Clemente López. 01/06/2020-05-2023. 30.000 €. Principal Investigator.

- **Las células mieloides supresoras como bioindicadores de la agresividad del curso clínico y de respuesta al tratamiento en esclerosis múltiple.** Instituto de Salud Carlos III (PI18/00357). Ministerio de Ciencia e Innovación. P.I. Dr. Diego Clemente López. 01/01/2029-31/12/2021. 255.310 €. Principal Investigator.

- **Estudio de las células mieloides supresoras monocíticas en la esclerosis múltiple primariamente progresiva** dentro del Consorcio Nacional "Estudio de los mecanismos fisiopatológicos que juegan un papel importante en las formas progresivas de Esclerosis Múltiple". Esclerosis Múltiple España- Red

Española de Esclerosis Múltiple. P.I. Dr. Diego Clemente López (National coordinator: Dr. L.M. Villar). 01-05-2018/30-04-2019. 50.000 € (6.500 € to our group). Principal Investigator.

- Células mieloides supresoras: diana terapéutica endógena para el tratamiento de la esclerosis múltiple. Aciturri Aeronáutica S.L., Vesuvius Ibérica LA, Galletas Coral Foundation, Spanish Association of Multiple Sclerosis. P.I. Dr Diego Clemente López. 1-01-17/28-02-19. 20.250 €. Principal Investigator.

- **Myeloid-derived suppressor cells and disease aggressiveness: a novel cell therapy to accelerate myelin repair in multiple sclerosis.** ARSEP Foundation Special Call for Proposals "Myelin: from lesion to repair". P.I. Dr Diego Clemente López (Transnational Coordinator: Dr. D. Clemente). 1-03-17/15-06-18.110.000 € (50.000 € for our group). Principal Investigator and Coordinator.

- **Member of the Spanish Network of Multiple Sclerosis (REEM)**. Spanish Ministry of Economy and Competitiveness. RD16/0015/0019. PI: Dr. Diego Clemente López (National coordinator: Dr. L.M. Villar). 1-01-16/31-12-18. 112.500 €. Principal Investigator.

- "**Métodos complementarios para la inmunomodulación de la actividad inflamatoria asociada a la esclerosis múltiple como herramienta neuro-reparadora**". Spanish Multiple Sclerosis Association. . PI: Dr. Diego Clemente López. 01-03-16/28-02-17. 7.000 €. Principal Investigator.

- "**Las células mieloides supresoras como biomarcadores de agresividad en esclerosis múltiple: relación con daño tisular y neuro-reparación**". Spanish Ministry of Economy and Competitiveness. PI15/00963. PI: Dr. Diego Clemente López. 1-01-16/31-12-18. 98.000 €. Principal Investigator.

- "**Mielina: desde la oligodendrogénesis a las enfermedades desmielinizantes-esclerosis múltiple**". Spanish Ministry of Economy and Competitiveness. (SAF2012-40023). PI: Dr. Fernando de Castro Soubriet (inititally) and Dr. Diego Clemente López (final PI). 1-1-2013/31-12-2015. Research member/Principal Investigator. Associated Fellowship for predoctoral students (former PFI). BES-2013-062630. PI: Dr. Diego Clemente López. 83.900 €.

- Initial Training Network "**nEUROinflammation**". Marie Curie Actions. Unión Europea-FP7. IP: Dr. Diego Clemente López (transnational coordinator Dr. Markus Schwaninger). 1-09-13/31-08-17. PI of the Associated partnership.

- "**Targeting tPA/NMDA interactions as a novel strategy of immunointervention in multiple sclerosis**". Special Call for Proposals "Immunointervention in demyelinating diseases of the Central Nervous System". ARSEP Foundation. IP: Dr. Diego Clemente López (coordinador: Dr. Fabian Docagne). 175.000 € (82.500 € for our group). 1-03-12/28-02-14. Principal Investigator.

- "**Estudio del receptor megalina y sus ligandos como posible diana terapéutica en enfermedades desmielinizantes**" Fundación para la Investigación Sanitaria de Castilla-La Mancha (FISCAM; PI-2009/26.). IP: Dr. Diego Clemente López. 1-01-10/31-12-12. 74.041,80 €. Principal Investigator.

5.- TECHNOLOGY CONTRACTS AND PATENTS

5.1. Contracts

- **Research on Neurodegenerative and Demyelinating Neurological Diseases.** Research agreement with Bristol Myers Squibb. P.I. Dr. Diego Clemente López. 1/09/2021-31/08/2022. 10.000 €. Principal investigator.

- **Effect of Evobrutinib on Myeloid-derived suppressor cell activity.** Research Agreement with Merck. P.I. Dr. Diego Clemente López. P.I. Dr. Diego Clemente López. 01/09/2020-31/08/2022. 308,991 €. Principal Investigator.

- **Glunomab-driven enhancing of myeloid-derived supresor cells.** Research Agreement with Paion Deutschland GmbH (Alemania). PI: Dr. Diego Clemente López. 2014-2016. 21.000 €.

5.2. Patents

- **Método para predecir las características histopatológicas de las lesiones de un sujeto con una enfermedad desmielinizante del sistema nervioso central**. Fernando de Castro Soubriet; Diego Clemente López; María Cristina Ortega Muñoz; Francisco Javier Arenzana Sanagérico. P200930661. Spain. 07/09/2009. Fundación del Hospital Nacional de Parapléjicos para la Investigación y la Integración.

- **Biomarcador para la clasificación histopatológica de lesiones de un sujeto con enfermedad desmielinizante del Sistema Nervioso Central**. Fernando de Castro Soubriet; Diego Clemente López; María Cristina Ortega Muñoz; Francisco Javier Arenzana Sanagérico. P201030090. Spain. 25/01/2010. Fundación del Hospital Nacional de Parapléjicos para la Investigación y la Integración.

6.- OTHER RESEARCH ACTIVITY

6.1. Honors

- 2003- Extraordinary Ph.D. Award. University of Salamanca. Salamanca, Spain.

- 2009- Best Scientific Communication at the IIIrd Internacional Meeting of Histology and Tissue Engineering: "Cell biology of oligodendrocyte precursors during development, in the adult CNS and implications in pathogenesis of demyelinating lesions: the FGF-2 dossier", by Fernando de Castro, Javier Arenzana, Mª Cristina Ortega, Ana Bribián, Pedro F. Esteban and Diego Clemente (Abstract published in: Histol. Histopatol. 24-Suppl. 1, S74). Albacete, Spain.

- 2010- Prize to the best poster at the 19th François Lhermitte's conferences. FRANCE-SPAIN Meeting on Multiple Sclerosis. ARSEP-FELEM. Paris, France.

- 2016- "*Esperanza (Hope)"* Award. Spanish Multiple Sclerosis Association in Toledo. Toledo, Spain.

- 2016- Honorary member of the Spanish Multiple Sclerosis Association in Miranda de Ebro. Miranda de Ebro, Spain.

- 2017. Honorific Mention in the 17th Edition of the Dr Antoni Esteve Foundation Research Award.

- 2017- Finalist in the IInd Fabiane Carvalho Miranda International Award from the research article "Neuroendothelial NMDA receptors as therapeutic targets in experimental autoimmune encephalomyelitis"; publiched in Brain 139; 2406–2419.

- 2021- VI Laia Acarín Award from the Spanish Glial Network, for the research paper "Myeloid-derived suppressor cells support remyelination in a murine model of Multiple Sclerosis by promoting oligodendrocyte precursor cell survival, proliferation and differentiation" published in GLIA (2021), 7:904-925.

- 2021. IInd “Esperanza” Award to the best Research Article about Multple Sclerosis from Esclerosis Múltiple Toledo for the "NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients" published in Brain (2020), 24:1414-30.

- 2022. “Research and Innovation Award (EXPERIMENTAL SCIENCES category)”, from the Regional Government of Castilla-La Mancha.

- 2022. “Science and Research Knowledge Award” from La Tribuna de Toledo journal.

6.2. Reviewer of research articles:

- Comparative Biochemistry and Physiology since 2004.
- PLoS ONE since 2012.
- Neuroscience Letters since 2012
- Frontiers in Cell Neuroscience since 2013.
- Glia since 2014.
- Journal of Neuroinflammation since 2015.
- Drug Design Therapy since 2016.
- International Journal of Neuroscience since 2016.
- European Journal of Neurology since 2016.
- Neuroscience since 2017.
- Expert Opinion in Biological Therapy since 2018.
- Annals of Neurology since 2022.
- Journal of Neuroimmunology since 2022.

6.3. Grant reviewer:

- *Fondazione Italiana Sclerosis Multipla* since 2014.
- Ministerio de Ciencia y Tecnología de Argentina since 2015.
- Spanish Agency of Evaluation and Prospective since 2015.
- Polish Agency of Science since 2015.
- French Agency of Science since 2023.

6.4. Formative capacity:

- 4 Doctoral thesis
- 6 Master Thesis.
- 8 Degree Thesis.
- Four postdoc fellows.
- Three technicians.

6.5. Organization of Research and Academic Events:

- 2005. Member of the Organizing Local Committee of the International Meeting on Implications of Comorbidity for Ethiology and Treatment of Neuropsychiatric Disorders. Fundación Cerebro y Mente.

Mazagón, Spain.

- 2015. Organizer of the International Symposium “Immune system control of brain damage and repair” . 16º Meeting of the Spanish Socienty for Neuroscience. Granada, Spain.

- 2015. Co-organizador of the Extraordinary Summer Course "New future perspectives in multiple sclerosis". University of Castille-La Mancha. Toledo, Spain.

- 2016. Director of the Summer Course "New advances and challenges in multiple sclerosis". Menéndez Pelayo International University. Santander, Spain.

- 2017. Organizing Committee of the 6th Spanish Glia Network Meeting. Alicante, Spain.

- 2017. Organizing Committee of the 1st Symposium of the Women in Neuroscience Committee of teh Spanish Society for Neurosciences. Alicante, Spain.

- 2017. Director of the Summer Course "New advances and challenges in multiple sclerosis-IInd Edition". Menéndez Pelayo International University. Santander, Spain.

- 2018. Director of the Summer Course "New advances and challenges in multiple sclerosis-IIIrd Edition". Menéndez Pelayo International University. Santander, Spain.

- 2019. Organizing Committee of the Spanish Glia Network Meeting. Santiago de Compostela, Spain.

- 2019. Director of the Summer Course "New advances and challenges in multiple sclerosis-IVth Edition". Menéndez Pelayo International University. Santander, Spain.

- 2020. Director of the Summer Course "New advances and challenges in multiple sclerosis-Vth Edition". Menéndez Pelayo International University. Santander, Spain.

- 2021. Director of the Summer Course "New advances and challenges in multiple sclerosis-VIth Edition". Menéndez Pelayo International University. Santander, Spain.

- 2022. Director of the Summer Course "New advances and challenges in multiple sclerosis-VIIth Edition". Menéndez Pelayo International University. Santander, Spain.

- 2023. Director of the Summer Course "New advances and challenges in multiple sclerosis-VIIIth Edition". Menéndez Pelayo International University. Santander, Spain.

6.6. Member of Committees and organizations

- 2021- Elected member of the Executive Board of the Spanish Society of Neuroscience.

- 2016- Member of the Women in Neuroscience Committee of the Spanish Society for Neuroscience.

- 2016-2021- Elected member of the Spanish Glia Network Executive Board.

- 2015- Scientific Advisor of the Spanish Multiple Sclerosis Association in Toledo (ADEM-TO).